Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter February 22, 2018

Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity

  • Swarup A.V. Shah ORCID logo , Minal U. Paradkar , Devendra C. Desai and Tester F. Ashavaid EMAIL logo

Abstract

Background:

Thiopurine methyltransferase (TPMT) gene variants have achieved limited success in predicting the outcome of thiopurine therapy, which shows wide inter-individual variations. The literature indicates a strong association between the NUDT15 gene variant and thiopurine-induced toxicity in Asian patients. The present study intends to explore the role of the NUDT15 variant (C415T) in Indian patients on thiopurine therapy.

Methods:

NUDT15 and TPMT genotyping were performed using amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR) and the restriction fragment length polymorphism (RFLP) technique.

Results:

Of 370 samples received for TPMT testing, 206 samples were available for NUDT15 genotyping. The NUDT15 risk allele frequency was 10.7%, with the frequency of wild, heterozygous and mutant genotypes being 80.6%, 17.5% and 1.9%, respectively. TPMT variants were seen in 13 of 370 (3.5%) patients, whereas the NUDT15 variant was seen in 40 of 206 (19.4%) patients. Thiopurine-induced toxicity information was available for 101 patients, among whom 10 developed leukopenia and all harbored the NUDT15 variant (p<0.0001). NUDT15 was clinically more relevant than TPMT in terms of sensitivity and specificity, as well as with a statistically significant difference in thiopurine dose requirement for patients with the NUDT15 variant.

Conclusions:

A preemptive NUDT15 genotyping approach can therefore help identify high-risk patients (NUDT15 C415T positive) who could benefit from thiopurine dose reduction, thereby preventing fatal thiopurine-induced toxicity.

Acknowledgments

The authors acknowledge the National Health Education Society of P.D. Hinduja National Hospital and Medical Research Centre for their financial support throughout the study.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: National Health Education Society of P.D. Hinduja National Hospital and Medical Research Centre.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interest: All authors have no conflict of interest to declare. The funding organization played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008;8:24–36.10.1038/nrc2292Search in Google Scholar PubMed

2. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006;25:1629–38.10.1038/sj.onc.1209372Search in Google Scholar PubMed

3. TPMT allele nomenclature. Available at: http://www.imh.liu.se/TPMTalleles/tabell-over-TPMT-alleler?l=en. Accessed 8 September, 2017.Search in Google Scholar

4. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387–91.10.1038/clpt.2010.320Search in Google Scholar PubMed PubMed Central

5. Ashavaid TF, Raghavan R, Shah S, Kapadia A, Almel S, Desai D. TPMT and DPD polymorphisms: efficient screening method for Indian patients considering taking thiopurine and 5-FU drugs. Dis Markers 2009;27:231–8.10.1155/2009/618407Search in Google Scholar

6. Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017–20.10.1038/ng.3060Search in Google Scholar PubMed PubMed Central

7. Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015;33:1235–42.10.1200/JCO.2014.59.4671Search in Google Scholar PubMed PubMed Central

8. Tanaka Y, Kato M, Hasegawa D, Urayama KY, Nakadate H, Kondoh K, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol 2015;171:109–15.10.1111/bjh.13518Search in Google Scholar PubMed

9. Kakuta Y, Naito T, Onodera M, Kuroha M, Kimura T, Shiga H, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J 2016;16:280–5.10.1038/tpj.2015.43Search in Google Scholar PubMed

10. Chiengthong K, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, Seksan P, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 2016;101:e24–6.10.3324/haematol.2015.134775Search in Google Scholar PubMed PubMed Central

11. Liang DC, Yang CP, Liu HC, Jaing TH, Chen SH, Hung IJ, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J 2016;16:536–9.10.1038/tpj.2015.75Search in Google Scholar PubMed

12. Lee YJ, Hwang EH, Park JH, Shin JH, Kang B, Kim SY. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn’s disease. Eur J Gastroenterol Hepatol 2016;28:475–8.10.1097/MEG.0000000000000564Search in Google Scholar PubMed

13. Zhu X, Wang XD, Chao K, Zhi M, Zheng H, Ruan HL, et al. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn’s disease. Aliment Pharmacol Ther 2016; 44:967–75.10.1111/apt.13796Search in Google Scholar PubMed

14. Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, et al. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol 2016;51:22–9.10.1007/s00535-015-1142-4Search in Google Scholar PubMed

15. Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016;48:367–73.10.1038/ng.3508Search in Google Scholar PubMed PubMed Central

16. Shah SA, Paradkar M, Desai D, Ashavaid TF. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients. J Gastroenterol Hepatol 2017;32:620–4.10.1111/jgh.13494Search in Google Scholar PubMed

Received: 2017-11-22
Accepted: 2018-1-23
Published Online: 2018-2-22
Published in Print: 2018-3-28

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 17.5.2024 from https://www.degruyter.com/document/doi/10.1515/dmpt-2017-0038/html
Scroll to top button